SEC filing summary
Entity discrepancy: Request metadata identifies Accendra Health Inc., but the supplied Form 10-Q is for Owens & Minor, Inc. This summary reflects the filing text. Reporting period: quarter and nine months ended September 30, 2023; filed November 3, 2023.
Business context
Owens & Minor operates Products & Healthcare Services, including medical distribution and manufactured/sourced products, and Patient Direct, including Byram and Apria home healthcare. Apria was acquired in March 2022, so the nine-month 2023 comparison includes Apria for the full period, unlike the comparable 2022 period.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net revenue | $2.592B | $2.497B | $7.678B | $7.404B |
| Gross margin | $538.5M; 20.78% | $513.3M; 20.55% | $1.555B; 20.26% | $1.419B; 19.17% |
| Operating income | $23.8M | $60.2M | $44.5M | $196.4M |
| Net income (loss) | $(6.4)M | $12.5M | $(59.1)M | $80.4M |
| Diluted EPS | $(0.08) | $0.16 | $(0.78) | $1.05 |
| Interest expense, net | $38.1M | $39.9M | $121.1M | $87.7M |
Cash flow: Nine-month operating cash flow was $628.9M, versus $238.0M in 2022. Investing used $98.3M, compared with $1.772B in 2022, which included the Apria purchase. Financing used $366.1M, versus $1.561B provided in 2022. Cash, cash equivalents and restricted cash at period end totaled $250.2M; balance-sheet cash and cash equivalents were $215.2M.
Debt and liquidity: Total debt carrying value was $2.146B at September 30, down from $2.501B at December 31, 2022; long-term debt excluding current maturities was $2.114B. The company repaid $270.2M of debt during the first nine months and repurchased debt principal. Its revolving credit facility was undrawn, with $423M available after letters of credit; the $450M receivables financing facility also had no borrowings. The company reported covenant compliance. Inventory fell to $1.084B from $1.334B, while accounts receivable declined to $682.7M from $763.5M.
Material changes and management commentary
- Q3 revenue rose 3.8%; nine-month revenue rose 3.7%. Patient Direct revenue increased 9.1% in Q3 and 31.2% year to date, supported by Apria and growth across product categories.
- Products & Healthcare Services revenue increased 2.1% in Q3 but declined 2.9% year to date. Lower PPE demand and pricing weighed on results; management cited an approximately $55M Q3 and $425M nine-month PPE revenue decline, including lower glove pricing. Non-PPE Medical Distribution sales grew.
- Operating income and earnings fell sharply, with $30.2M of Q3 and $74.8M of nine-month exit and realignment charges, compared with $2.0M and $4.9M, respectively, in 2022. The 2023 charges primarily involved the Operating Model Realignment Program and IT restructuring. Management expects additional material program costs but said they could not be reasonably estimated.
- Patient Direct operating income was $64.4M in Q3 and $169.3M for nine months, versus $59.7M and $127.8M. Products & Healthcare Services operating income was $19.8M and $24.6M, versus $23.8M and $174.1M.
- Management said cash from operations, available financing, and cash on hand should be sufficient for foreseeable working capital, capital spending, debt and other requirements. No specific earnings or revenue guidance is provided. The company notes sales have historically been higher in the third and fourth quarters.
Risks, contingencies and unusual items
- N95 respirators: Following FDA and NIOSH product-performance concerns, the company voluntarily recalled one lot and temporarily stopped U.S. sales of certain products. On September 29, 2023, the FDA updated its recommendation to permit use of the two referenced models under their labeling, excluding the recalled lot, and sales resumed. The company cannot estimate potential losses; returns, further recalls, regulatory action, litigation or other remedial costs could be material.
- Goodwill: Management cited adverse industry and macroeconomic effects on the Global Products and Apria reporting units, including higher interest rates, inflation, pricing pressures and lower demand. Further adverse changes could result in impairment.
- Tax dispute: The IRS disputes the company’s transfer-pricing treatment for 2015–2018. The company disagrees and believes its reserve is adequate, but warns an adverse outcome could materially affect results or cash flows.
- Interest-rate exposure: The filing estimates a 100-basis-point increase could reduce annual pre-tax earnings by approximately $8M, after swaps and considering the maximum RPA receivable balance.
- Receivables program: The company began selling receivables under a separate limited-recourse purchase agreement in 2023; nine-month net proceeds were $888M, and $89.1M of sold receivables remained uncollected at quarter end. Sales generated $7.1M of losses in other operating expense year to date.
- Other stated risks include pricing and competition, supplier/customer concentration and performance, integration and restructuring execution, product safety and regulation, foreign exchange, commodity and freight costs, substantial indebtedness, and potential litigation. The company said there were no material changes to the risk factors in its prior annual report.
Important facts for investors to verify
- Confirm the filing is for Owens & Minor, not the company named in the request metadata.
- Track whether restructuring costs continue to rise and whether anticipated savings improve operating results.
- Assess PPE demand/pricing trends, Patient Direct growth and the comparability impact of the Apria acquisition.
- Monitor debt repayment, interest expense, liquidity and the company’s reliance on receivables sales for cash generation.
- Follow developments in the N95 matter, the IRS dispute and goodwill impairment indicators.